Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s core claim (rodent thyroid C-cell tumor findings, unknown human relevance, contraindication in MTC/MEN 2, and counseling about symptoms) is directly supported by the provided label excerpts, with no apparent contradictions.
Category Scores
Accurate Statements
Tirzepatide/MOUNJARO poses a risk of thyroid C-cell tumors; human relevance is unknown.
Section 5.1: rat dose- and treatment-duration-dependent increase in thyroid C-cell tumors and “It is unknown whether MOUNJARO causes thyroid C-cell tumors… in humans.”
Patients with MTC or MEN 2 are contraindicated.
Section 4: contraindicated in patients with personal or family history of MTC or MEN 2.
Counseling about thyroid tumor symptoms is included.
Section 5.1: counsel patients regarding potential risk for MTC and inform them of symptoms of thyroid tumors.
Unsupported Statements
Contradictions
Important Omissions
The label also specifies that routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements align with the label’s contraindication and thyroid C-cell tumor risk language; however, the response does not mention the label’s statement about uncertain value of routine calcitonin/ultrasound monitoring.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: the label’s guidance that routine calcitonin/thyroid ultrasound monitoring is of uncertain value is not included in the evaluated claim.
Suggested Improvement
Add the label’s statement regarding the uncertain value of routine calcitonin monitoring and thyroid ultrasound for early detection of MTC.